The National Institute on Drug Abuse recently awarded more than $11 million to a Yale School of Medicine research team for its opioid use disorder initiative.
The five-year initiative, Addressing Risk Through Community Treatment for Infectious Disease and Opioid Use Disorder Now (ACTION), will compare Patient Navigation to Mobile Health Unit service delivery for people released from prisons and jails who have a history of opioid use and/or injection drug use and who are either living with HIV or at risk of acquiring HIV.
This group will be given access to community-based HIV, and opioid use disorder prevention and treatment service care. Care includes medications for opioid use disorder, syringe services programs, hepatitis C treatment, antiretroviral therapy, and pre-exposure prophylaxis.
The initiative is a multi-site collaboration between Yale University, the University of Texas Southwestern, Texas Christian University, and community and Department of Corrections partners.
Researchers will conduct their study in Connecticut’s New London, Windham, and Tolland counties. These areas have high rates of HIV and hepatitis C related to injection drug use and have been struck by the opioid epidemic.
The team is led by Dr. Sandra Springer, associate professor of infectious diseases and associate clinical professor of nursing.